203 results on '"Losonsky G"'
Search Results
2. Safety and Immunogenicity of Salmonella typhi Ty21a Liquid Formulation Vaccine in 4- to 6-Year-Old Thai Children
3. 176 A Randomized Controlled Trial of Rsv Prophylaxis with Motavizumab Vs Palivizumab in Young Children with Hemodynamically Significant Congenital Heart Disease
4. 891 Population Pharmacokinetics Analysis of Motavizumab in Children at Risk for Respiratory Syncytial Virus Infection
5. Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection
6. Evaluation of a bivalent (CVD 103-HgR/CVD 111) live oral cholera vaccine in adult volunteers from the United States and Peru
7. Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system
8. Vibriocidal antibody responses in North American volunteers exposed to wild-type or vaccine Vibrio cholerae O139: specificity and relevance to immunity
9. RISK FACTORS FOR NOSOCOMIAL BACTEREMIA IN EXTREMELY LOW BIRTHWEIGHT INFANTS. 1353
10. Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans
11. No Adverse Impact on Protection against Pertussis from Combined Administration of Haemophilus infiuenzae Type b Conjugate and Diphtheria-Tetanus Toxoid-Pertussis Vaccines in the Same Syringe
12. Vibrio cholerae 01 Can Assume a Chlorine-Resistant Rugose Survival Form that Is Virulent for Humans
13. Safety, immunogenicity, and transmissibility in humans of CVD 1203, a live oral Shigella flexneri 2a vaccine candidate attenuated by deletions in aroA and virG
14. Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908
15. Engineered deltaguaB-A deltavirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine
16. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera
17. Further characterization of delta aroA delta virG Shigella flexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli
18. Initial Clinical Studies of CVD 112 Vibrio cholerae O139 Live Oral Vaccine: Safety and Efficacy against Experimental Challenge
19. Clinical and Immunologic Characteristics of Vibrio cholerae O139 Bengal Infection in North American Volunteers
20. Attenuated live cholera vaccine strain CVD 103-HgR elicits significantly higher serum vibriocidal antibody titers in persons of blood group O
21. Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine
22. Successful Treatment of Meningitis Due to Multiply Resistant Enterococcus faecium with a Combination of Intrathecal Teicoplanin and Intravenous Antimicrobial Agents
23. Salmonella typhi Vaccine Strain CVD 908 Expressing the Circumsporozoite Protein of Plasmodium falciparum: Strain Construction and Safety and Immunogenicity in Humans
24. Serum antibody responses of divers to waterborne pathogens
25. Safety and Immunogenicity of Live Oral Cholera Vaccine Candidate CVD 110, a ctxA ctxAzot zotace Derivative of El Tor Ogawa Vibrio cholerae
26. Long-Term Persistence of Sterile Immunity in a Volunteer Immunized with X-Irradiated Plasmodium falciparum Sporozoites
27. Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels
28. Role of the eaeA gene in experimental enteropathogenic Escherichia coli infection.
29. Safety and immunogenicity of Salmonella typhi Ty21a vaccine in young Thai children
30. Secondary Vibrio cholerae-specific cellular antibody responses following wild-type homologous challenge in people vaccinated with CVD 103-HgR live oral cholera vaccine: changes with time and lack of correlation with protection
31. Asymptomatic Infections Due to Wild-Type Rotavirus May Prime for a Heterotypic Response to Vaccination with Rhesus Rotavirus
32. Human immune response to Campylobacter jejuni proteins expressed in vivo
33. Safety and immunogenicity in North Americans of a single dose of live oral cholera vaccine CVD 103-HgR: results of a randomized, placebo-controlled, double-blind crossover trial
34. Safety and immunogenicity of a booster dose of Vibrio cholerae CVD 103-HgR live oral cholera vaccine in Swiss adults
35. Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine.
36. Antibodies to shiga holotoxin and to two synthetic peptides of the B subunit in sera of patients with Shigella dysenteriae 1 dysentery
37. Humoral immune responses to VP4 and its cleavage products VP5* and VP8* in infants vaccinated with rhesus rotavirus
38. Rotavirus-Specific Breast Milk Antibody in Two Populations and Possible Correlates of Interference with Rhesus Rotavirus Vaccine Seroconversion
39. Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers
40. Immunogenicity of Salmonella typhi Ty21a vaccine for young children
41. Immunogenicity of Vibrio cholerae O1 toxin-coregulated pili in experimental and clinical cholera
42. Lack of Immune Response to the Vi Component of a Vi-Positive Variant of the Salmonella typhi Live Oral Vaccine Strain Ty21a in Human Studies
43. Mucosal Immunity Induced by Enhanced-Potency Inactivated and Oral Polio Vaccines
44. Challenge Studies in Volunteers Using Escherichia coli Strains with Diffuse Adherence to HEp-2 Cells
45. Diminished immunogenicity of a recombination-deficient derivative of Vibrio cholerae vaccine strain CVD103
46. Experimental non-O group 1 Vibrio cholerae gastroenteritis in humans.
47. The Immune Response in Primary Asymptomatic and Symptomatic Rotavirus Infection in Newborn Infants
48. Experimental Human Infections with Giardia lamblia.
49. Attenuated Shigella flexneri 2a vaccine strain CVD 1204 expressing colonization factor antigen I and mutant heat-labile enterotoxin of enterotoxigenic Escherichia coli.
50. Role of EspB in experimental human enteropathogenic Escherichia coli infection.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.